Chiesi Farmaceutici Hires New CEO After $1.48bn Amryt Acquisition

Move of the month

Chiesi Farmaceutici hires new CEO after $1.48bn Amryt acquisition

Chiesi Farmaceutici, a family-owned Italian pharmaceutical company, has appointed Giuseppe Accogli as group CEO. This comes after 2020’s $1.48bn acquisition of rare disease specialist Amryt.

Accogli has 25 years’ experience in the pharma industry, most recently at Baxter in its renal sector. Before then, he was at Italian medtechs Medtronic and Tyco Healthcare. Accogli’s background spans sales, marketing, product innovation, R&D and M&A, where he focused on the EMEA and US markets.

Giuseppe Accogli stated: “I am honoured to lead Chiesi into its new stages of growth and I thank the Board of Directors for their trust and the opportunity they are giving me to be part of such an exciting journey. At its core, Chiesi is a group of innovative and highly committed professionals who care for the health and well-being of people around the world leaving a positive impact in the environment and the communities in which the company operates. As CEO, I strive to enable our leaders, people and partners to achieve even greater success in fulfilling this commitment to be a sustainable force for good in the biopharmaceutical industry.”

Alberto Chiesi, President of Chiesi Group, says, “We are thrilled to have Giuseppe in the CEO role. He is a proven leader with the vision and the strength to expand on the success Chiesi has built over the past 85 years and take us into our next phase of growth and innovation.”

Amryt, another Italian company, currently has three FDA-approved drugs: Juxtapid for homozygous familial hypercholesterolemia, Myalept for lipodystrophy and Mycapssa for acromegaly. It also has Filsuvez, which was approved in the EU in 2022.

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

The biotechnology company foghorn therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be replacing Sam Agresta after his retirement on 11 September 2023.

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

The Helmholtz Centre for Infection Research (HZI), Germany, has appointed professor Josef Penninger as scientific director.

Olav Hellebø to join Cytovation’s board of directors

Cytovation, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has appointed Olav Hellebø to its board of directors.

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

Olav Hellebø to join Cytovation’s board of directors

Reacta appoints Kevin Hawkins as new head of regulatory affairs

Simon Sinclair appointed as chief medical officer of Ondine Biomedical

Pharmafocus

Categories

Social Footprints